Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H16O6 |
Molecular Weight | 376.3588 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C2C(O)=CC3=C4C2=C(C(O)=C1)C(=O)C5=C4C(=C(O)C=C5O)C(=O)C3(C)C
InChI
InChIKey=ABLACSIRCKEUOB-UHFFFAOYSA-N
InChI=1S/C22H16O6/c1-7-4-9(23)15-18-13(7)10(24)5-8-14(18)19-16(20(15)27)11(25)6-12(26)17(19)21(28)22(8,2)3/h4-6,23-26H,1-3H3
Heliomycin was isolated as a stable polyketide antibiotic substance produced by Streptomyces resistomycificus. Heliomycin has been shown to demonstrate antibacterial activity against gram-positive bacteria and mycobacteria. Heliomycin preferentially inhibits RNA synthesis in comparison to DNA and protein synthesis in intact bacterial cells. Heliomycin is indicated for the treatment of various dermatological pathologies, including pyoderma, pemphigus or pemphigus of newborns, trophic ulcers infected secondarily, microbial eczema, cracked nipples in women breastfeeding a baby, pseudofurunculosis and others. Since heliomycin is low in toxicity, the only contraindication is increased individual intolerance to the components of the ointment. It is cytotoxic to gastric adenocarcinoma HMO2 cells and hepatic carcinoma HePG2 cells.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364672 |
|||
Target ID: DNA polymerase (bacterial) Sources: https://www.ncbi.nlm.nih.gov/pubmed/812270 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.rlsnet.ru/mnn_index_id_128.htm |
Curative | Heliomycin Approved UseIndicated for the treatment of pyoderma, infected eczema, ulcers, pressure sores, varicose trophic ulcers, cracks (especially in the nipple area of nursing mothers), pemphigus of newborns, rhinitis. |
||
Primary | Heliomycin Approved UseIndicated for the treatment of pyoderma, infected eczema, ulcers, pressure sores, varicose trophic ulcers, cracks (especially in the nipple area of nursing mothers), pemphigus of newborns, rhinitis. |
|||
Curative | Heliomycin Approved UseIndicated for the treatment of pyoderma, infected eczema, ulcers, pressure sores, varicose trophic ulcers, cracks (especially in the nipple area of nursing mothers), pemphigus of newborns, rhinitis. |
PubMed
Title | Date | PubMed |
---|---|---|
3-Alkanoyl-5-hydroxymethyl tetronic acid homologues and resistomycin: new inhibitors of HIV-1 protease. I. Fermentation, isolation and biological activity. | 1994 Feb |
|
Phylum-specific regulation of resistomycin production in a Streptomyces sp. via microbial coculture. | 2015 Mar 27 |
|
Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives. | 2018 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rusmedserv.com/lekarstva/geliomitsin.html
Locally, 1-2 times per day for 5-7 days or more
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12440735
Resistomycin inhibited apoptosis induced by actinomycin D (AD) with or without acceleration by colcemid (CL) in human megakaryoblastic leukemia CMK-7 cells, IC50 for inhibition against AD-induced apoptosis was about 0.5 uM and IC50 for inhibition against AD plus CL-induced apoptosis was about 1 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C75147
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
C007912
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
20004-62-0
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
SUB08013MIG
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1320139
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
DTXSID4046101
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
m9542
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
7N3A092A5X
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
100000083928
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
3053
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY | |||
|
5282060
Created by
admin on Fri Dec 15 15:29:17 GMT 2023 , Edited by admin on Fri Dec 15 15:29:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY